ResearchBib Share Your Research, Maximize Your Social Impacts
Sign for Notice Everyday Sign up >> Login

A study of prevalence of polymorphic variants of genes of blood coagulation factors in onco-logical patients

Journal: I.P. Pavlov Russian Medical Biological Herald (Vol.28, No. 1)

Publication Date:

Authors : ;

Page : 44-56

Keywords : polymorphic sites; genes of blood coagulation factors; thrombotic complications; oncology;

Source : Downloadexternal Find it from : Google Scholarexternal


Aim. To study the prevalence of carriage of polymorphic allele variants of genes of blood coagulation factors in oncological patients. Materials and Methods. 213 Patients with morphologically confirmed oncological diseases were examined. Samples of genomic DNA of peripheral blood of the patients were examined. Using polymerase chain reaction (PCR), polymorphic sites of genes of hemostatic system were studied in real time: F2 (G20210А, rs1799963), F5 (G1691A, rs6025), F7 (G10976A, rs6046), F13 (G226A, rs5985), FGB G(-455)A (rs1800790), ITGA2-α2 (C807T, rs1126643), ITGB3-b (Т1565С, rs5918), PAI-1 4G(-675)5G, rs1799889). Results. The prevalence of carriage of alternative allele of F2 (G20210А) polymorphic locus in the studied group was 1.6%, of F5 (G1691A) – 3.5%, of F7 (G10976A) – 13.4%, of F13 (G226A) – 28.2%, of FGB G(-455)A – 24.9%, of ITGA2-α2 (C807T) – 41.5%, of ITGB3-b (Т1565С) – 15.5%, of PAI-1 4G(-675)5G – 56.6%. A statistically significant increase in the frequency of ‘risk alleles' of F5 G1691A (р=0.0169), F13 G226A (р=0.0007), FGB G(-455)A (р<0.0001) and ITGA2-α2 C807T (р=0.0201) polymorphic loci was found in oncological patients as compared to the general population. In the same loci, except ITGA2-α2 (C807T), statistically significant differences in the frequency of alternative alleles were found in different localizations of the oncological process. In 92.0% of patients, SNR combination was determined in different components of hemostatic system. Conclusion. Taking into account a high frequency of identification of ‘risk alleles' in all components of hemostatic system, it is reasonable to carry out additional research to determine the necessity of addition of antiaggregants to antithrombotic therapy in oncological patients.

Last modified: 2020-04-10 22:45:23